No photo of Reem Karmali

View Scopus Profile

Reem Karmali

  • 686 Citations
20082024

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Training Experience

2009Residency, Rush University Medical Center
2012Fellowship, Rush University Medical Center

Education/Academic qualification

MS, Rush University

… → 2012

MD, University of Western Ontario

… → 2006

Fingerprint Dive into the research topics where Reem Karmali is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 17 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants

Prot #JCAR017-BCM-003: A Global Randomized Multicenter Phase 3 Trial to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects with High-Risk, Transplant-Eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TR

Karmali, R.

ICON Clinical Research, LLC, Celgene Corporation

10/21/19 → 10/21/22

Project: Research project

Prot #NDS-NHL-001: A Global, Non-Interventional, Retrospective, Multi-Center Study To Generate Real-World Evidence Of Treatment Outcomes In Subjects With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Karmali, R.

Quintiles, Inc., Celgene Corporation

9/18/19 → 9/18/24

Project: Research project

Prot #NEER-01: Network for Enigmatic Exceptional Responders to Cancer Treatment - The Cure is NEER

Karmali, R.

Takeda Pharmaceuticals U.S.A., Inc., Millennium Pharmaceuticals, Inc

6/12/19 → 6/12/22

Project: Research project

Prot #X34001/NU 18H02: A Phase 1 Study of R-CHOP Plus SYK Inhibitor TAK-659 for the Front-Line Treatment of High-Risk Diffuse Large B cell Lymphoma (DLBCL)

Karmali, R.

GMA Research Corporation, Millennium Pharmaceuticals, Inc

2/19/19 → 2/19/22

Project: Research project

Prot #GC-LTFU-001: Long-term Follow-up Protocol for Subjects Treated with Gene-Modified T Cells

Karmali, R.

ICON Clinical Research, LLC, Celgene Corporation

1/8/19 → 1/8/22

Project: Research project

Research Output

  • 686 Citations
  • 34 Article
  • 4 Review article
  • 1 Chapter

Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation

Hamadani, M., Khanal, M., Ahn, K. W., Litovich, C., Chow, V. A., Eghtedar, A., Karmali, R., Winter, A., Fenske, T. S., Sauter, C., Kharfan-Dabaja, M. A. & Awan, F. T., Jan 1 2020, (Accepted/In press) In : Biology of Blood and Marrow Transplantation.

Research output: Contribution to journal › Article

    • Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma

    Merryman, R. W., Carreau, N. A., Advani, R. H., Spinner, M. A., Herrera, A. F., Chen, R., Tomassetti, S., Ramchandren, R., Hamid, M., Assouline, S., Santiago, R., Wagner-Johnston, N., Paul, S., Svoboda, J., Bair, S. M., Barta, S. K., Liu, Y., Nathan, S., Karmali, R., Burkart, M. & 13 others, Torka, P., David, K. A., Wei, C., Lansigan, F., Emery, L., Persky, D., Smith, S. M., Godfrey, J., Chavez, J., Cohen, J. B., Troxel, A. B., Diefenbach, C. & Armand, P., Jan 1 2020, (Accepted/In press) In : Oncologist.

    Research output: Contribution to journal › Article

    Open Access

    • Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure

    Ayers, E. C., Li, S., Medeiros, L. J., Bond, D. A., Maddocks, K. J., Torka, P., Mier Hicks, A., Curry, M., Wagner-Johnston, N. D., Karmali, R., Behdad, A., Fakhri, B., Kahl, B. S., Churnetski, M. C., Cohen, J. B., Reddy, N. M., Modi, D., Ramchandren, R., Howlett, C., Leslie, L. A. & 20 others, Cytryn, S., Diefenbach, C. S., Faramand, R., Chavez, J. C., Olszewski, A. J., Liu, Y., Barta, S. K., Mukhija, D., Hill, B. T., Ma, H., Amengual, J. E., Nathan, S., Assouline, S. E., Orellana-Noia, V. M., Portell, C. A., Chandar, A., David, K. A., Giri, A., Hess, B. T. & Landsburg, D. J., Jan 15 2020, In : Cancer. 126, 2, p. 293-303 11 p.

    Research output: Contribution to journal › Article

    • 2 Scopus citations

    Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics

    Torka, P., Kothari, S. K., Sundaram, S., Li, S., Medeiros, L. J., Ayers, E. C., Landsburg, D. J., Bond, D. A., Maddocks, K. J., Giri, A., Hess, B., Pham, L. Q., Advani, R., Liu, Y., Barta, S. K., Vose, J. M., Churnetski, M. C., Cohen, J. B., Burkart, M., Karmali, R. & 12 others, Zurko, J., Mehta, A., Olszewski, A. J., Lee, S., Hill, B. T., Burns, T. F., Lansigan, F., Rabinovich, E., Peace, D., Groman, A., Attwood, K. & Hernandez-Ilizaliturri, F. J., Jan 28 2020, In : Blood Advances. 4, 2, p. 253-262 10 p.

    Research output: Contribution to journal › Article

    Open Access

    • Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy

    Landsburg, D. J., Ayers, E. C., Bond, D. A., Maddocks, K. J., Karmali, R., Behdad, A., Curry, M., Wagner-Johnston, N. D., Modi, D., Ramchandren, R., Assouline, S. E., Faramand, R., Chavez, J. C., Torka, P., Mier Hicks, A., Medeiros, L. J. & Li, S., Apr 1 2020, In : British Journal of Haematology. 189, 2, p. 313-317 5 p.

    Research output: Contribution to journal › Article

    • 1 Scopus citations